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A Common Variant at the 14q32 Endometrial Cancer Risk
Locus Activates AKT1 through YY1 Binding
Jodie N. Painter,1 Susanne Kaufmann,1 Tracy A. O’Mara,1 Kristine M. Hillman,1 Haran Sivakumaran,1
Hatef Darabi,2 Timothy H.T. Cheng,3 John Pearson,1 Stephen Kazakoff,1 Nicola Waddell,1
Erling A. Hoivik,4,5 Ellen L. Goode,6 Rodney J. Scott,7,8,9,10 Ian Tomlinson,3 Alison M. Dunning,11
Douglas F. Easton,11,12 Juliet D. French,1 Helga B. Salvesen,4,5 Pamela M. Pollock,13
Deborah J. Thompson,12 Amanda B. Spurdle,1 and Stacey L. Edwards1,*
A recent meta-analysis of multiple genome-wide association and follow-up endometrial cancer case-control datasets identified a novel
genetic risk locus for this disease at chromosome 14q32.33. To prioritize the functional SNP(s) and target gene(s) at this locus, we
employed an in silico fine-mapping approach using genotyped and imputed SNP data for 6,608 endometrial cancer cases and 37,925
controls of European ancestry. Association and functional analyses provide evidence that the best candidate causal SNP is rs2494737.
Multiple experimental analyses show that SNP rs2494737 maps to a silencer element located within AKT1, a member of the PI3K/
AKT/MTOR intracellular signaling pathway activated in endometrial tumors. The rs2494737 risk A allele creates a YY1 transcription fac-
tor-binding site and abrogates the silencer activity in luciferase assays, an effect mimicked by transfection of YY1 siRNA. Our findings
suggest YY1 is a positive regulator of AKT1, mediating the stimulatory effects of rs2494737 increasing endometrial cancer risk. Identi-
fication of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors
by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as
chemopreventive agents in individuals at high risk of developing endometrial cancer.Introduction
Endometrial cancer (MIM: 608089) (cancer of the lining of
the uterine corpus) is the fourth most diagnosed cancer in
women in Europe and North America.1,2 To date, analyses
of multiple genome-wide association study (GWAS) and
follow-up datasets, comprising up to 7,737 endometrial
cancer cases and 37,144 controls, have identified seven
risk loci at genome-wide significance for this disease,
including HNF1B (MIM: 189907),3,4 CYP19A1 (MIM:
107910),5 and novel loci on chromosomes 13q22.1,
6q22.31, 8q24.21, 15q15.1, and 14q32.33.6 The lead SNP
at the 14q32.33 locus, rs2498796, represents a single asso-
ciation signal located in the region of the AKT1 (MIM:
164730) oncogene.6 AKT1 is a member of the P13K/AKT/
MTOR intracellular signaling pathway affecting cell sur-
vival and proliferation.7 This gene is of particular interest
for endometrial cancer as increased PI3K/AKT/MTOR
signaling is a common occurrence in endometrial tumors,
and in aggressive subtypes in particular.8 Somatic alter-
ations in one or more members of the PI3K/AKT/MTOR
signaling pathway are common, with PTEN (MIM:
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levels of phosphorylated AKT have been associated with
aggressive disease.8,10,11 Our previous bioinformatic anal-
ysis indicated that rs2498796 and other SNPs in high link-
age disequilibrium (LD) with this SNP might also regulate
other nearby genes SIVA1 (MIM: 605567), ZBTB42
(MIM: 613915), ADSSL1 (MIM: 612498), and INF2 (MIM:
610982).6 Here, we detail in silico fine-mapping and bio-
informatic investigation of an expanded set of genotyped
and imputed SNPs at 14q32.33, derived from the meta-
analysis dataset described above, and multiple laboratory
analyses to identify the functional SNP(s) and target
gene(s) increasing endometrial cancer risk at this locus.Material and Methods
Previously, meta-analysis of data for 7,737 endometrial cancer
cases and 37,144 controls of European ancestry from three
GWAS datasets (ANECS, SEARCH, and NSECG) and two follow-
up datasets (iCOGs and NSECG Phase 2) identified rs2498796
(OR ¼ 1.12 for the minor A allele, 95% CI:1.07–1.17, p value ¼
3.553 108) as the top SNP representing a single association signal
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study we employed an in silico fine-mapping approach12 previ-
ously used to fine-map other endometrial cancer risk loci,4,5,13,14
focussing on the 1Mb region surrounding rs2498796 (bases
104,743,220-105,743,220; NCBI build 37/hg19 assembly). The
current analysis utilized genotyped and imputed SNP data for
the three GWAS (ANECS, SEARCH, and NSECG) and the iCOGs
follow-up datasets and included a total of 6,608 endometrial can-
cer cases and 37,925 controls (details of these datasets can be
found in4,5). The Cheng et al. analysis had included a total of
420 genotyped and imputed SNPs with minor allele frequencies
(MAF) R1% and information scores R0.9 per dataset within
the focal region.6 To expand the search for potentially functional
SNPs, we considered all genotyped and imputed SNPs (N ¼ 2,922)
with MAF R1% and information scores R0.4 per dataset. As
described previously4, regional imputation to the 1,000 Genomes
v3 2012 release was conducted separately for each of the four
datasets, based on inference panels of SNPs typed for each dataset,
using IMPUTE v2.15 Association testing was performed separately
for each dataset using frequentist tests with a logistic regression
model in SNPTEST v2.16, and standard fixed effects meta-analysis
using the beta estimates and standard errors per dataset conducted
using METAL.17 The regional association plot was created using
LocusZoom.18 Log-likelihood tests were used to determine the
most likely causal SNPs by comparing the log-likelihoods obtained
from the meta-analysis of our top SNPs (p < 10-6) with that of
the most significantly associated SNP. SNPs with odds of 100:1
or better of being the top SNP were prioritized as potential causal
candidates for bioinformatic and functional analyses.4,19,20 LD be-
tween SNPs was calculated from European Phase 3 1000 Genomes
data and accessed from the National Cancer Institute LDlink
tool.21Bioinformatic Analysis
Bioinformatic analyses on SNPs prioritized by the log-likelihood
tests were performed using publically available datasets from
ENCODE22, which includes information such as the location of
promoter and enhancer histone marks, open chromatin, bound
proteins and altered motifs for the Ishikawa endometrial cancer
cell line. Data from Hnisz et al.23 and PreSTIGE24 was accessed to
identify the location of likely enhancers and their gene targets
in a cell-specific context.Expression Analyses
Expression quantitative trait locus (eQTL) analyses were conduct-
ed using uterine tissue-specific data (N ¼ 70) generated by the Ge-
notype-Tissue Expression Project (GTEx)25, and SNP (Affymetrix
6.0 arrays), RNA-seq and copy number (CNV) data for endometrial
carcinoma samples (N ¼ 526) and normal tissue samples adjacent
to endometrial carcinoma (N ¼ 29) obtained from restricted (SNP
and RNA-Seq) and public (CNV) data portals of The Cancer
Genome Atlas (TCGA).26 For the TCGA data, to investigate the
expression of all AKT1 isoforms, including unannotated tran-
scripts, unprocessed RNA-Seq FASTQ files were adapter trimmed
using cutadapt (v1.8.1) and aligned to the Ensembl27 GRCh37
reference (version 70) using STAR28 (v2.4.2a). RNA-SeQC29
(v1.1.8.1) was used to assess sequencing quality for all aligned
data. Gene and transcript counts were estimated using RSEM30
(v1.2.22). Genotypes for AKT1 region SNPs present in the 1000
Genomes v3 2012 dataset which were not present on the Affyme-
trix 6.0 arrays were imputed using MaCH31,32 and minimac33,34
software. eQTL analyses were performed on transcripts expressed1160 The American Journal of Human Genetics 98, 1159–1169, Junein >80% of samples using Kruskal-Wallis tests adjusting for copy
number and sequencing method, with Bonferroni corrected
p values < 0.006 (0.05/8 transcripts per SNP) considered statisti-
cally significant.Cell Lines
Endometrial cancer cell lines Ishikawa and EN-1078D (both het-
erozygous for the SNPs under investigation) were grown in
DMEM medium with 10% FCS and antibiotics. Cell lines were
maintained under standard conditions, routinely tested for
Mycoplasma and short tandem repeat (STR) profiled to confirm
cell line identity.Chromatin Conformation Capture
Chromatin conformation capture (3C) libraries were generated us-
ing NcoI as described previously.35 3C interactions were quanti-
tated by real-time PCR (qPCR) using primers designed within
restriction fragments (Table S1). All qPCR was performed on a
RotorGene 6000 using MyTaq HS DNA polymerase (Bioline)
with the addition of 5 mM of Syto9, annealing temperature of
66C and extension of 30 s. 3C analyses were performed in three
independent 3C libraries from each cell line with each experiment
quantified in duplicate. BAC clones covering the 14q32 region
were used to create artificial libraries of ligation products in order
to normalize for PCR efficiency. Data were normalized to the signal
from the BAC clone library and, between cell lines, by reference to
a region within GAPDH (MIM: 138400).35 All qPCR products were
electrophoresed on 2% agarose gels, gel purified, and sequenced to
verify the 3C product.Electromobility Shift Assays
Gel shift assays were performed with Ishikawa and EN-1078D nu-
clear lysates and biotinylated oligonucleotide duplexes (Table S2).
Nuclear lysates were prepared using the NE-PER nuclear and cyto-
plasmic extraction reagents (Thermo Fisher Scientific) as per the
manufacturer’s instructions. Total protein concentrations in nu-
clear lysates were determined by Bradford’s method. Duplexes
were prepared by combining sense and antisense oligonucleotides
in NEBuffer2 (New England Biolabs) and heat annealing at 80C
for 10 min and slow cooling to 25C for 1 hr. Binding reactions
were performed in binding buffer (10% [vol/vol] glycerol,
20 mM HEPES [pH 7.4], 1 mM DTT, protease inhibitor cocktail
[Roche], 0.75 mg poly[dI:dC] [Sigma-Aldrich]) with 7.5 mg of nu-
clear lysate. For competition assays, binding reactions were pre-
incubated with 1 pmol of competitor duplex (Table S3) at 25C
for 10 min before the addition of 10 fmol of biotinylated oligo
duplex and a further incubation at 25C for 15 min. For gel-super-
shift assays, 5 mg of rabbit polyclonal YY1 antibody (Santa Cruz
H-414) or C/EBP antibody (Santa Cruz sc-150) was added immedi-
ately before probe addition. The rabbit pre-immune IgG (Santa
Cruz sc-2027) was used as a negative control. Reactions were sepa-
rated on 10% (WT/vol) Tris-Borate-EDTA (TBE) polyacrylamide
gels (Bio-Rad) in TBE buffer at 160 V for 40 min. Duplex-bound
complexes were transferred onto Zeta-Probe positively-charged
nylon membranes (Bio-Rad) by semi-dry transfer at 25 V for
20 min then cross-linked onto the membranes under 254 nm
ultra-violet light for 10 min. Membranes were processed with
the LightShift Chemiluminescent EMSA kit (Thermo Fisher Scien-
tific) as per the manufacturer’s instructions. Chemiluminescent
signals were visualized with the C-DiGit blot scanner (LI-COR).2, 2016
Table 1. Association of the Top Candidate Causal SNPs at Chromosome 14q32.33 with Endometrial Cancer Risk
SNP Position (Build 19) Minor allele Common allele MAFa OR (95% CI)b p value r2 to rs2498796 Likelihood ratioc
rs2498794 105245251 G A 0.48 1.13 (1.09–1.17) 8.7 3 109 0.43 1
rs2494737 105246325 A T 0.30 1.13 (1.08–1.17) 2.5 3 107 0.83 26
rs2498796 105243220 A G 0.30 1.11 (1.07–1.16) 1.2 3 106 – 120
aMinor (risk-increasing) allele frequency.
bOR for the effect allele.
cRatio of the likelihood of rs2498794 to the likelihood of this SNP.Plasmid Construction and Reporter Assays
Promoter-driven luciferase reporter constructs were generated by
the insertion of PCR amplified fragments containing AKT1 canon-
ical (can), AKT1 alternative (alt), or ZBTB42 promoters into the
MluI and BglII sites of pGL3-Basic. A 2537 bp fragment containing
a putative regulatory element (PRE) identified by bioinformatic
analysis was generated by PCR and cloned into BamHI and SalI
sites of themodified pGL3-promoter constructs (Table S4). Themi-
nor (risk-increasing) alleles of individual SNPs were introduced
into the PRE sequences by overlap extension PCR or gBlocks (Inte-
grated DNATechnologies). Sequencing of all constructs confirmed
variant incorporation (Australian Genome Research Facility).
Ishikawa and EN-1078D cells were transfected with equimolar
amounts of luciferase reporter plasmids and 50 ng of pRL-SV40
transfection control plasmid with Lipofectamine 2000. The total
amount of transfected DNA was kept constant at 600 ng for
each construct by the addition of pUC19 as a carrier plasmid.
Luciferase activity was measured 24 hr post-transfection by the
Dual-Glo Luciferase Assay System. To correct for any differences
in transfection efficiency or cell lysate preparation, we normalized
Firefly luciferase activity to Renilla luciferase and measured the ac-
tivity of each construct relative to the promoter alone construct,
which had a defined activity of 1. Statistical significance was tested
by log transforming the data and performing two-way ANOVA,
followed by Dunnett’s multiple comparisons test in GraphPad
Prism.siRNA Silencing for Reporter Assays
Two Silencer Select siRNAs against YY1 (siYY1; s224779) and a
Silencer Select nontargeting siRNA (siCON; 4390843) were pur-
chased from Life Technologies (Thermo Fisher Scientific). For
silencing, Ishikawa cells were co-transfected with the relevant
luciferase reporter plasmids and 100 nM of either YY1 or non-tar-
geting siRNAs with Lipofectamine 2000. Luciferase assays were
performed as described above after 72 hr. qPCR was performed
as described previously36 to validate YY1 knockdown.Chromatin Immunoprecipitation
Ishikawa cells were cross-linked with 1% formaldehyde at 37C for
10 min, rinsed once with ice-cold PBS containing 5% BSA and
once with PBS, and harvested in PBS containing 1X protease in-
hibitor cocktail (Roche). Harvested cells were centrifuged for
2 min at 3,000 rpm. Cell pellets were resuspended in 0.35 mL of
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1X
protease inhibitor cocktail) and sonicated 3 times for 15 sec at
70% duty cycle (Branson SLPt) followed by centrifugation at
13,000 rpm for 15 min. Supernatants were collected and diluted
in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl, pH 8.1). Two micrograms of antibody was pre-The Americbound for 6 hr to protein G Dynabeads (Life Technologies) and
then added to the diluted chromatin for overnight immuno-
precipitation. The magnetic bead-chromatin complexes were
collected and washed six times in RIPA buffer (50 mM HEPES
[pH 7.6], 1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 0.5 M
LiCl), then twice with TE buffer. To reverse the cross-linking, the
magnetic bead complexes were incubated overnight at 65C in
elution buffer (1% SDS, 0.1 M NaHCO3). DNA fragments were pu-
rified using a QIAquick Spin Kit (Qiagen). For qPCR, 2.0 uL from a
100 uL immunoprecipitated chromatin extraction and 40 cycles of
amplification were used. All PCR products were sequenced by
Sanger sequencing (AGRF). Antibodies used were anti-NFkB p50
(06-886), anti-YY1 (sc-1703-X), and control IgG (sc-2027). ChIP
primers are listed in Table S5.Results
Association and Likelihood Testing at the 14q32.33
Endometrial Cancer Risk Locus Prioritizes Three SNPs
for Follow-Up
A total of 2,922 SNPs with MAF R1% and information
scoresR0.4 per endometrial cancer dataset were included
in the fine-mapping analysis, representing 76.6% of the
SNPs with a MAF R1% in the 1000 Genomes 2012 refer-
ence panel in this region (hg19 chr14: 104,743,220-
105,743,220; Table S6). Considering SNPs correlated
(r2 > 0.2) with rs2498796, the previously reported top
endometrial cancer risk SNP at this locus,6 coverage was
good, with >94% of correlated SNPs in the same 1000
Genomes reference panel represented in each dataset.
Association and log-likelihood tests prioritized two SNPs
for bioinformatic and functional follow-up: rs2498794
(OR ¼ 1.13, 95% CI 1.09–1.17, p value 8.7 3 10-9) and
rs2494737 (OR ¼ 1.13, 95% CI 1.08–1.17, p value 2.5 3
10-7; Table 1 and Table S7). No other SNP was significant
at p < 1 3 10-4 in analyses conditioning on rs2498794 or
rs2494737 (r2 to each other 0.54, Table S7), confirming
the single association signal at this locus (Figure 1). As
SNP rs2498796 (p value 1.2 3 10-6 in the current analysis,
r2 to rs2498794 0.43, and to rs2494737 0.83; Table 1) was
the original endometrial cancer risk SNP reported for
this locus, it was also included in the bioinformatic and
functional analyses detailed below. Neither rs2498794
nor rs2494737 had been reported in our previous
genome-wide analysis because of the more stringent impu-
tation threshold used in that study.an Journal of Human Genetics 98, 1159–1169, June 2, 2016 1161
Figure 1. Regional Association Plot for the 14q32.33 Endome-
trial Cancer Risk Locus
The location (Build 19) and –log10 p value of the original top SNP
at this locus, rs2498796,6 is shown in purple; all other SNPs are
shown in colors corresponding to their r2 (linkage disequilibrium)
value with rs2498796.The Top Candidate SNPs Fall within a Putative
Regulatory Element that Frequently Interacts with
AKT1 and ZBTB42 Promoter Regions
Analysis of cis enhancer-gene interactions using data from
Hnisz et al.23 and PreSTIGE24 identified AKT1, ZBTB42,Figure 2. Regulatory Landscape at the 14q32.33 Endometrial Can
(A) The location of the candidate SNPs are represented by black ticks,
with exons (vertical boxes) joined by introns (lines). The subset of en
the candidate causal SNPs are shown as colored bars, where the colorm
(H3K4Me1, indicative of regulatory regions; H3K4Me3, indicative of
hypersensitivity (indicative of open chromatin, with darker shading
(TF) binding in multiple ENCODE cell lines are indicated at the bott
(B) Zoomed-in view of the location of candidate SNPs, PRE, and nea
1162 The American Journal of Human Genetics 98, 1159–1169, JuneSIVA1, ADSSL1, and INF2 as potential candidate target
genes of a PRE located in the region containing the top
candidate SNPs (Figure 2). To determine the target gene(s)
of the PRE, we performed chromosome conformation cap-
ture (3C) using an anchor primer within the PRE and
primers within restriction fragments spanning all protein
coding gene promoters within 2Mb of the PRE. The results
showed that the PRE frequently interacted with a canoni-
cal and alternative promoter of AKT1 and the ZBTB42 pro-
moter in both Ishikawa and EN-1078D endometrial cancer
cells (Figures 3A and 3B). To assess any potential impact
of SNP rs2494737 on chromatin looping, we performed
allele-specific 3C in heterozygous Ishikawa cell lines.
A primer was designed to incorporate the rs2494737 into
the 3C PCR products, which were then Sanger sequenced.
The sequence profiles indicate that the cancer risk- and
non-risk-associated rs2494737 alleles form loops with
the AKT1 and ZBTB42 promoters with equal efficiencies
(Figure S1). No significant interactions were detected be-
tween the PRE and other flanking genes including SIVA1,
ADSSL1, INF2, and CEPB170B (Figure 3A and Figure S2).SNP rs2494737 Affects the Regulatory Capability of
the PRE on AKT1 Promoter Regions
The regulatory capability of the PRE, combined with the
effects of candidate SNPs, was examined in luciferasecer Risk Locus
and the PRE is shown as a black box. Gene structures are depicted
hancers predicted in Hnisz et al.23 and PreSTIGE24 which overlap
atches its predicted gene target. Regions showing histone binding
promoters; and H3K27Ac, indicative of active enhancers), DNAseI
indicating stronger experimental signal) and transcription factor
om of the panel.
rby gene promoter regions.
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Figure 3. Candidate Causal SNPs Are
Located within a PRE that Interacts with
the AKT1 and ZBTB42 Promoter Regions
(A) 3C interaction profiles between the PRE
and local genes in Ishikawa and EN-1078D
endometrial cancer cell lines. The 3C an-
chor (which contains the PRE) is shown
as a grey box and significant interactions
are outlined.
(B) Zoomed-in view of significant interac-
tions. AKT1 Can and AKT1 Alt denote a
canonical and alternative AKT1 promoter
(prom) region, respectively. 3C libraries
were generatedwithNcoI. Graphs represent
three biological replicates. Error bars repre-
sent SD. Regions cloned into reporter gene
constructs are shown as grey horizontal
boxes.reporter assays in Ishikawa and EN-1078D cell lines. PRE
constructs containing the reference (common, protective)
alleles of the three candidate SNPs significantly reduced
their associated target gene promoter activities, suggesting
that the PRE can act as a transcriptional silencer (Figure 4
and Figure S3). Inclusion of the minor (risk-increasing)
allele of rs2494737 significantly increased the canonical
and alternative AKT1 promoter activities in both cell
lines, but had no effect on the ZBTB42 promoter. In
contrast, inclusion of the minor (risk-increasing) alleles
of SNPs rs2498796 and rs2498794 had no significant ef-
fects on AKT1 or ZBTB42 promoter activities (Figure 4
and Figure S3).
The Risk Allele of SNP rs2494737 Binds the YY1
Transcription Factor
We used bioinformatic analyses and functional studies to
examine DNA-protein interactions for the three candidate
SNPs. In silico prediction tools including HaploReg37
and Alibaba238 predicted all three SNPs to alter transcrip-
tion factor (TF) binding (Table S8 and Figure S4). We per-
formed electrophoretic mobility shift assays (EMSAs)
to assess binding of TFs to the common (protective) and
minor (risk-increasing) alleles of each of these SNPs and
showed allele-specific protein binding for rs2494737 and
rs2498796 (Figure 5A and Figure S5). Competition with
TF binding sites suggested that YY1 binds to the minor
(risk-increasing) allele of rs2494737 and NF-kB binds to
the common allele of rs2498796 (Figure 5B and Figure S5).
No other predicted TFs were able to compete for binding at
either site, including CEBPA, AP2, and CREB (Figure S5).
Supershift assays using anti-YY1 antiserum indicated that
the protein binding the minor allele of rs2494737 is likely
to be YY1 (Figure S6). Chromatin immunoprecipitation
(ChIP) in heterozygous Ishikawa cells confirmed occu-
pancy of YY1 binding in vivo and showed it is preferen-
tially recruited to the minor A (risk-increasing) allele ofThe Americrs2494737 (Figures 5C and 5D and Figure S7). The impor-
tance of YY1 binding was confirmed in cotransfection as-
says that showed that two independent siRNAs against
YY1 repressed the promoter activation in the presence
of the minor A allele of rs2494737 (Figure 5E and
Figure S8). We found no evidence of CEBPA binding to
the rs2494737 site or NF-kB binding to the rs2498796
site in vivo.Gene-Expression Analysis in Uterine Tissue
Association between SNPs in the AKT1 region and AKT1
mRNA expression was investigated in both normal and
endometrial tumor tissue. In the GTEx dataset, with the
three candidate SNPs as input, rs2497896 was associated
with increased AKT1 expression in normal uterine tissue
(sample N ¼ 70, p ¼ 0.01, Figure S9), but no eQTL effect
was detected for rs2494737 or rs2498794, suggesting a
stochastic effect due to the reasonably small sample size
as these SNPs are in moderate to high LD with each other.
Performing an eQTL search for AKT1 in uterine tissue
returned no results. However, including all GTEx tissues re-
vealed all three candidate SNPs, and others in moderate to
high LD, to be highly significantly associated with AKT1
expression in thyroid tissue (N ¼ 278; rs2494737 ¼ 3.6 3
1014, rs2498796 ¼ 5.1031025, and rs2498794¼6.1 3
1019; Table S7), indicating these SNPs are eQTLs for
AKT1 in some cellular contexts. In the TCGA datasets, no
SNP in the AKT1 region was associated with differential
AKT1 expression of any isoform in normal endometrial
tissue (N ¼ 29) or in endometrial tumors (N ¼ 526;
Figure S10).Discussion
In the largest association study for endometrial cancer to
date, a recent meta-analysis of five GWAS and follow-upan Journal of Human Genetics 98, 1159–1169, June 2, 2016 1163
Figure 4. The Risk Allele of SNP rs2494737 Enhances AKT1 Pro-
moter Activity
Luciferase reporter assays following transient transfection of Ishi-
kawa endometrial cancer cell lines. The putative regulatory
element (PRE) containing the major SNP alleles were cloned
downstream of target gene promoter-driven luciferase constructs.
AKT1 can and AKT1 alt denote a canonical and alternative AKT1
promoter (prom) region, respectively. Minor (risk-increasing)
SNP alleles were engineered into the constructs and are designated
by the rs ID of the corresponding SNP. Haplotype denotes a
construct that contains the minor alleles of rs2498796 and
rs2494737. Error bars denote 95% confidence intervals from three
independent experiments performed in duplicate. P values were
determined by 2-way ANOVA followed by Dunnett’s multiple
comparisons test (**p < 0.01, ****p < 0.0001).datasets revealed the presence of one multi-variant haplo-
type at the 14q32.33 chromosomal locus associated with
the risk of this cancer.6 In consideration of the fact that
our genotyping platforms were not specifically designed
for fine-mapping of this region, we conducted in silico
fine-mapping of the 14q32 region using SNPs with imputa-
tion scores down to 0.4. We identified two SNPs as most
likely to be the causal SNPs increasing endometrial cancer
risk in this region: SNPs rs2498794 and rs2494737, inmod-
erate and high LD, respectively, with the original hit at
this locus rs2498796.6 Multiple laboratory analyses then
confirmed that rs2494737 has a functional impact on the
AKT1 oncogene, a gene of potential biological relevance
to endometrial cancer risk as other PI3K pathway muta-
tions have been detected in precursor lesions of complex
atypical endometrial hyperplasia.39
Our fine-mapping, together with multiple lines of
bioinformatic and experimental evidence indicate that
rs2494737 is the functional SNP most likely to be relevant
for endometrial cancer at the 14q32 risk locus. However,
additional bioinformatic analyses indicated multiple regu-
latory elements across the region that contained several1164 The American Journal of Human Genetics 98, 1159–1169, Juneless significantly risk-associated SNPs. Additionally, our
SNP coverage of the region was not complete, although
~98% of SNPs in at least moderate LD (r2 > 0.2), and
100% of SNPs in high LD (r2 > 0.8), with rs2498796 in
the 1000 Genomes 2012 panel were also present in our
datasets, and imputed to high quality scores (>0.71).
Therefore, we cannot rule out the possibility that addi-
tional SNPs exert effects on AKT1 expression via alterna-
tive mechanisms. For example, at the well-characterized
8q24 risk locus, multiple risk-associated enhancers interact
with MYC in a tissue-specific manner.40 Furthermore, a
few recent studies have indicated that risk-associated
SNPs might also influence epigenetic features,41,42 adding
yet another layer of complexity to the control of gene
expression.
Publicly available enhancer data frommultiple cell types
indicate that the region harboring rs2494737 might target
a number of genes in the 14q32 region, some of which are
highly plausible endometrial cancer candidate genes. Our
3C analyses show that in endometrial tumor cells the
rs2494737 region specifically targets AKT1 and ZBTB42,
while luciferase assays showed that the rs2494737 minor
A (risk-increasing) allele affects only AKT1, increasing
the activity of both the canonical and an alternative pro-
moter. Therefore, we expect the causal risk allele to result
in increased expression of one or more AKT1 isoforms
in vivo. Although we observed no significant effect of the
rs2494737 minor allele on overall or isoform-specific
AKT1 expression in normal uterine or endometrial tumor
tissue, there are multiple possible explanations. One
reason could be that the risk allele affects AKT1 expression
in endometrial epithelial cells that represent only a frac-
tion of the total cells in a normal uterine sample, which
is composed of substantially more endometrial stromal
cells as well as underlying myometrium. Any effect on
expression might also occur only in specific cellular con-
texts. Further, the lack of association in the normal tissue
sample sets examined might also be due to low power,
with only 47% and 23% power to detect an effect of a
SNP (MAF 0.3) explaining even 5% of the variance in
AKT1 expression in the GTEx and TCGA datasets, respec-
tively. We had 99.9% power to detect the same effect in
the larger (N ¼ 526) endometrial tumor dataset, although
here any eQTL effect might be difficult to detect due to
the overall increase in AKT1 expression seen in endome-
trial tumor cells in general. The apparent discrepancy be-
tween eQTL results and our in vitro findings is not unprec-
edented: functional SNPs in CCND1 (MIM: 168461)36 and
MYC (MIM: 190080)43 show no association with gene
expression in human tumor cells, although one MYC re-
gion SNP (rs6983267) has been demonstrated to have a
functional effect in vivo.43
AKT1, a serine/threonine kinase highly expressed in the
endometrium,44 regulates many processes including cell
metabolism, proliferation, survival, growth, and angiogen-
esis45 and is already of considerable interest as a potential
therapeutic target for endometrial cancer.9,46 Activation2, 2016
Figure 5. The Risk Allele of rs2494737
Demonstrates Allele-Specific YY1 Binding
(A) EMSAs to detect allele-specific binding
of nuclear proteins. Oligonucleotides were
incubated with Ishikawa nuclear extracts.
Red arrowheads show bands of different
mobility detected between the common (C)
and minor (risk-increasing) (m) alleles for
the candidate causal SNPs.
(B) Oligonucleotides for SNP rs2494737 were
incubated with Ishikawa nuclear extracts.
Red arrowhead indicates the band that was
competed for complex formation on the mi-
nor (m) allele. Competitor oligonucleotides
are listed above each panel and were used
at 100-fold molar excess: () no competitor;
(Neg) a non-specific competitor; (YY1)
consensus binding site; (YY1m) an identical
oligonucleotide but with a mutated binding
site.
(C) ChIP–qPCR on SNP rs2494737 in hetero-
zygous Ishikawa cell lines. ChIP assays were
performed with YY1 antibody or non-im-
mune IgG, a region 3.2kb upstream of the
predicted YY1-binding site served as a
negative control (Control). Graphs represent
two biological replicates. Error bars denote
SD. P-values were determined with a two-
tailed t-test (**p < 0.01).
(D) Sanger sequencing of the PCR fragment generated using primers flanking SNP rs2494737 following YY1 ChIP-qPCR and the input
DNA controls.
(E) Luciferase assays in Ishikawa cells shows the effect of YY1 siRNA silencing on the activity of the AKT1 canonical (can) and alternative
(alt) promoter regions with the PRE containing the reference T allele (canþPRE; altþPRE) or the risk A allele (rs2494737). Error bars
denote 95% confidence intervals from three independent experiments performed in duplicate. P values were determined by two-way
ANOVA followed by Dunnett’s multiple comparisons test (**p < 0.01, ***p < 0.001). The level of YY1 silencing is shown in Figure S8.of the PI3K/AKT/mTOR intracellular signaling pathway, of
which AKT1 is a member, occurs in numerous cancers9,45
and up to 80% of endometrial tumors.47 This pathway acti-
vation has been linked to somatic mutations and copy-
number alterations in various PI3K/AKT/mTOR pathway
genes, including inactivating mutations and deletion of
the PTEN tumor-suppressor gene and activating mutations
or amplifications in the PIK3R1 (MIM: 171833) and/or
PIK3CA genes.48 AKT1 mutations are rare, with an onco-
genic c.49G>A (p.Glu17Lys) (NM_005163.2) mutation
occurring in only ~2%of endometrial tumors,10,11 and acti-
vation is thought to result from the concomitant loss or
activation of upstream pathway proteins.48
Our results indicate a possible additional mechanism
whereby the presence of a common SNP allele results in
increased AKT1 transcriptional activity mediated through
YY1 and results in an increased risk of endometrial cancer.
YY1 is found at elevated levels in numerous cancers,
including breast (MIM: 114480), prostate (MIM: 176807),
and cervical cancers (MIM: 603956),49 and was recently
demonstrated to be over-expressed particularly in early
stage (I and II) endometrial tumors, indicating this tran-
scription factor could be a molecular marker of early tumor
development.50 Of note, YY1 knockdown using small
inferring RNA (siRNA) and small hairpin RNA (shRNA)
reduced YY1 protein levels, decreased cell proliferation
and reduced cell motility of the AN3CA endometrial can-
cer cell line, while siYY1 injected directly into xenograft tu-The Americmors in mice delayed endometrial tumor growth.50
Although these data would suggest YY1 is a potential
therapeutic target, transcription factors are notoriously
hard to target with small molecules. The data presented
here suggests that elevated levels of YY1 are oncogenic
in part through upregulation of AKT1 expression, which
is a signaling pathway that is more amenable to drug
targeting.51
Activation of AKT1 requires translocation to the plasma
membrane followed by phosphorylation of the Thr308
and Ser473 residues: high levels of p-AKT1 are a marker of
poor prognosis in endometrial and other cancers.8,52,53 A
large number of inhibitors targeting mTOR and/or PI3K
have been tested in early clinical trials in multiple tumor
types, however, toxicity issues have complicated their
ongoing development and many have not been taken for-
ward into large phase III trials. Several AKT inhibitors are
also in development, and initial clinical activity recently re-
ported in several different solid tumor types including
breast, lung, and gynaecological tumors carrying the
AKT1 c.49G>A (p.Glu17Lys) hotspot mutation.54,55 There
is a current emphasis on reducing systemic toxicities by
optimizing scheduling as well as evaluating nanoparticles
to target these agents to tumors and reduce systemic
exposure,56 nonetheless it is unlikely that AKT inhibitors
developed for treatment of metastatic disease will have an
acceptable toxicity profile to be used as chemopreventive
agents.an Journal of Human Genetics 98, 1159–1169, June 2, 2016 1165
A promising alternative might be the re-positioning
of the type 2 diabetes drug metformin. This drug has
multiple mechanisms of action targeting both meta-
bolism, by decreasing circulating glucose levels, as well as
altering intracellular signaling by activating AMPK.57
Activation of AMPK has been shown to inhibit mTOR, a
downstream effector of PI3K/AKT signaling. Metformin is
currently being evaluated in the adjuvant treatment of
endometrial cancer58 as well as large chemoprevention tri-
als (e.g. the Diabetes Prevention Program Outcomes
Study). It would be interesting to determine the out-
come analyses from these large-scale chemoprevention tri-
als if patients were genotyped and retrospectively stratified
based on their germline AKT1 risk alleles. Perhaps the abil-
ity of metformin to blunt mTOR signaling would
be reflected in a greater decrease in endometrial cancer
incidence in the AKT1 SNP carriers treated with
metformin.
Although our data indicate that AKT1 is the likely target
gene, it is possible that these SNPs also exert functional ef-
fects through long-range control of other genes under
different conditions of cell activation or in other cell
types, including nearby SIVA1, ZBTB42, ADSSL1, and
INF2. Notably, SIVA1 is reported to activate and suppress
apoptosis, a process dysregulated in cancer. Among other
roles, SIVA1 can inhibit p53 tumor suppressor functions
and is mutated in up to 90% of aggressive endometrial
tumors.26,59 ZBTB42 (zinc finger and BTB domain contain-
ing 42) is a poorly characterized member of the C2H2
zinc finger protein family60. It is highly expressed in
subsynaptic nuclei in skeletal muscles underlying the
neuromuscular junctions,60 and might be involved in
muscle development.61 ADSSL1 (Adenylosuccinate Syn-
thase Like 1) is a muscle isozyme that is selectively deleted
in carcinogen-induced mouse lung adenocarcinomas.62
While INF2 (Inverted Formin 2) encodes a member of the
diaphanous-related formin family, which is involved in
remodelling the actin and microtubule cytoskeltons.63
Mutations in this gene are reported to cause a form of auto-
somal-dominant focal and segmental glomerulosclerosis
and Charcot-Marie-Tooth disease.64,65
In conclusion, we have identified a common SNP allele
associated with endometrial cancer risk that functions to
increase AKT1 expression through YY1-mediated tran-
scription. Identification of an endometrial cancer risk allele
within amember of the PI3K/AKT signaling pathway, more
commonly activated in tumors by somatic alterations, rai-
ses the possibility that well-tolerated inhibitors targeting
this pathway could be candidates for evaluation as chemo-
preventive agents in individuals at high risk of developing
endometrial cancer.Supplemental Data
Supplemental Data includes ten figures, eight tables, and Supple-
mental Experimental Procedures and can be found with this
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